000874903 001__ 874903
000874903 005__ 20230217124536.0
000874903 0247_ $$2doi$$a10.1093/noajnl/vdz038
000874903 0247_ $$2Handle$$a2128/24699
000874903 0247_ $$2pmid$$apmid:32642667
000874903 0247_ $$2WOS$$aWOS:000886002700031
000874903 037__ $$aFZJ-2020-01691
000874903 1001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b0$$eCorresponding author
000874903 245__ $$aImaging findings following regorafenib in malignant gliomas: FET PET adds valuable information to anatomical MRI
000874903 260__ $$aOxford$$bOxford University Press$$c2019
000874903 264_1 $$2Crossref$$3online$$bOxford University Press (OUP)$$c2019-10-20
000874903 264_1 $$2Crossref$$3print$$bOxford University Press (OUP)$$c2019-05-01
000874903 264_1 $$2Crossref$$3print$$bOxford University Press (OUP)$$c2019-05-01
000874903 3367_ $$2DRIVER$$aarticle
000874903 3367_ $$2DataCite$$aOutput Types/Journal article
000874903 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1587470944_11511
000874903 3367_ $$2BibTeX$$aARTICLE
000874903 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000874903 3367_ $$00$$2EndNote$$aJournal Article
000874903 520__ $$aThe prospective REGOMA phase 2 trial showed an encouraging and significant median progression-free and overall survival (PFS, OS) benefit for glioblastoma patients at first progression treated with the oral multikinase inhibitor regorafenib compared to lomustine monotherapy.1 In particular, the OS benefit was 1.8 months compared to lomustine (7.4 vs. 5.6 months; P = .0009), and the hazard ratio was 0.5 (95% confidence interval, 0.33–0.75). Interestingly, despite unchanged MRI findings at first follow-up (“Stable Disease,” 39%) following regorafenib, complete or partial radiological responses according to the RANO criteria2 were only seen in 5% of cases treated with regorafenib. On the other hand, 59% of patients in the regorafenib arm had grade 3–4 adverse events.
000874903 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000874903 542__ $$2Crossref$$i2019-10-20$$uhttp://creativecommons.org/licenses/by-nc/4.0/
000874903 588__ $$aDataset connected to CrossRef
000874903 7001_ $$0P:(DE-HGF)0$$aWerner, Jan-Michael$$b1
000874903 7001_ $$0P:(DE-Juel1)168559$$aTscherpel, Caroline$$b2
000874903 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R$$b3
000874903 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b4
000874903 77318 $$2Crossref$$3journal-article$$a10.1093/noajnl/vdz038$$bOxford University Press (OUP)$$d2019-05-01$$n1$$tNeuro-Oncology Advances$$v1$$x2632-2498$$y2019
000874903 773__ $$0PERI:(DE-600)3009682-0$$a10.1093/noajnl/vdz038$$gp. vdz038$$n1$$pvdz038$$tNeuro-oncology advances$$v1$$x2632-2498$$y2019
000874903 8564_ $$uhttps://juser.fz-juelich.de/record/874903/files/vdz038.pdf$$yOpenAccess
000874903 8564_ $$uhttps://juser.fz-juelich.de/record/874903/files/vdz038.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000874903 909CO $$ooai:juser.fz-juelich.de:874903$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000874903 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b0$$kFZJ
000874903 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b3$$kFZJ
000874903 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b4$$kFZJ
000874903 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000874903 9141_ $$y2020
000874903 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000874903 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000874903 920__ $$lyes
000874903 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000874903 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000874903 980__ $$ajournal
000874903 980__ $$aVDB
000874903 980__ $$aUNRESTRICTED
000874903 980__ $$aI:(DE-Juel1)INM-3-20090406
000874903 980__ $$aI:(DE-Juel1)INM-4-20090406
000874903 9801_ $$aFullTexts
000874903 999C5 $$1Lombardi$$2Crossref$$9-- missing cx lookup --$$a10.1016/S1470-2045(18)30675-2$$p110 -$$tLancet Oncol.$$v20$$y2019
000874903 999C5 $$1Wen$$2Crossref$$9-- missing cx lookup --$$a10.1200/JCO.2009.26.3541$$p1963 -$$tJ Clin Oncol.$$v28$$y2010
000874903 999C5 $$1Tzaridis$$2Crossref$$9-- missing cx lookup --$$a10.1093/neuonc/noz071$$tNeuro Oncol$$y2019
000874903 999C5 $$1Kebir$$2Crossref$$9-- missing cx lookup --$$a10.1007/s00432-019-02868-5$$p1037 -$$tJ Cancer Res Clin Oncol.$$v145$$y2019
000874903 999C5 $$1Albert$$2Crossref$$9-- missing cx lookup --$$a10.1093/neuonc/now058$$p1199 -$$tNeuro Oncol.$$v18$$y2016
000874903 999C5 $$1Langen$$2Crossref$$9-- missing cx lookup --$$a10.1038/nrneurol.2017.44$$p279 -$$tNat Rev Neurol.$$v13$$y2017